Fetal Cardiac Care

by Dr Mridul Agarwal
, ,

Fetal Supraventricular Tachycardia: The Evolving Role of Flecainide vs. Digoxin (And What We Await from the FAST Trial)

13–19 minutes

Dr. Mridul Agarwal, MD, FNB (Paediatric Cardiology)
Senior Consultant, Paediatric Cardiac Sciences · Sir Ganga Ram Hospital, New Delhi
AHA 2024 / PACES Evidence Review

Last Reviewed: November 2026

Executive Summary & Guideline Evolution

For decades, transplacental digoxin served as the conventional first-line therapy for fetal supraventricular tachycardia (SVT), largely due to long-standing clinical familiarity. However, pharmacological and clinical studies have identified a critical challenge: in hydrops fetalis, the fetal-to-maternal digoxin concentration ratio decreases substantially – from approximately 0.70–0.85 in non-hydropic pregnancies to 0.20–0.30 in edematous placentas.

This pharmacological distinction is reflected in contemporary consensus statements, including the 2024 AHA Scientific Statement on Fetal & Neonatal Arrhythmias (Batra et al., Circulation 2024), endorsed by the Pediatric & Congenital Electrophysiology Society (PACES): transplacental flecainide (for SVT) and sotalol (for atrial flutter) are now widely recognized as preferred first-line medications across many tertiary referral centers. While the randomized FAST Trial (NCT02624765) has completed follow-up and its primary publication is awaited, contemporary clinical practice has increasingly adopted flecainide as a cornerstone therapy.

⚡ Clinical Decision Matrix & Safety Protocol
Batra 2024 AHA · FAST Protocol



First-Line Approach

1st-Line: Flecainide Monotherapy

⚠️ Inpatient Initiation: Administer strictly under pediatric cardiology and MFM supervision with daily 12-lead ECG.
Initial Maternal Dose
Flecainide 100 mg PO TID (300 mg/d)
Initial Dose (<50 kg mother)
50–100 mg PO BID
Placental Transfer
Fetal: Maternal Ratio ~0.80–1.0
Observed Conversion Rate
50% at 5 days, 63% at 10 days (all treated SVT, Jaeggi 2011)
Secondary / Adjunct
Add Digoxin or switch to Sotalol

Key Clinical Rationale

Most fetal SVTs represent orthodromic AV reentrant tachycardia (AVRT) involving an accessory pathway. Flecainide selectively depresses retrograde accessory pathway conduction and fast sodium channels (INa).

Comparative Evidence: In multicenter retrospective cohorts (Jaeggi et al. 2011), flecainide showed superior hazard ratios for SVT termination than sotalol and higher sustained cardioversion rates than digoxin in hydropic fetuses (Alsaied et al. 2017).

Critical Care Strategy

Urgent Inpatient Admission

🚨 Placental Hydrops Impairs Digoxin: Fetal-to-maternal digoxin concentration decreases to <0.30. Do not rely on digoxin monotherapy.
First-Line Therapy
Flecainide 100 mg PO TID
Combination Regimen
Flecainide + Digoxin (IV loading)
Placental Transfer
Fetal: Maternal Ratio ~0.80–1.0 Preserved
Conversion Rate
Higher conversion odds vs. Digoxin (Alsaied 2017)
Refractory Rescue
IV Amiodarone or Direct Fetal Therapy

Hydrops Pathophysiology Note

Placental stromal edema creates a physical diffusion barrier to large hydrophilic molecules like digoxin. Flecainide is lipophilic with modest protein binding, crossing the edematous syncytiotrophoblast to deliver therapeutic fetal levels.

Refractory Management: In fetuses with deteriorating biophysical profile or refractory failure, maternal IV amiodarone or direct ultrasound-guided fetal intervention in specialized tertiary centres may be considered.

Atrial Flutter Protocol

1st-Line: Sotalol Monotherapy

⚠️ Maternal Torsades Risk: Inpatient telemetry mandatory. Monitor maternal QTc interval strictly (<480 ms).
Initial Maternal Dose
Sotalol 80–160 mg PO BID
Maximum Typical Dose
Up to 320–480 mg/day under strict ECG telemetry
Mechanism
Class III (IKr) + Beta-Blockade
Termination Hazard Ratio
HR = 5.4 vs Digoxin; HR = 7.4 vs Flecainide
Secondary Option
Add Digoxin for AV nodal conduction control

Why Sotalol Is Preferred in Flutter

Atrial flutter is a macro-reentrant atrial circuit. Class III potassium channel blockade prolongs atrial refractoriness, terminating the circuit. In the cohort by Jaeggi et al., sotalol showed significantly higher termination hazard ratios for atrial flutter than digoxin or flecainide.

Maternal Safety Benchmark: Sotalol prolongs ventricular repolarization. If maternal QTc exceeds 480 ms, sotalol must be withheld or the dose reduced immediately.

📈 Bedside Flecainide QRS Safety Monitor

Because serum flecainide assay results may have delayed turnaround, serial maternal 12-lead ECG QRS duration measurement is the primary real-time clinical surrogate for sodium channel blockade. Test maternal values below:



+11.8% widening: Conduction delay is within safe therapeutic limits (<20% widening and QRS ≤120 ms). Safe to maintain current regimen under daily ECG monitoring.
SAFE (GREEN)

1. Pathophysiology and the Digoxin Paradox

When a fetus develops sustained supraventricular tachycardia (commonly orthodromic AVRT with ventricular rates between 220 and 280 bpm), abbreviated diastolic filling times markedly impair stroke volume and cardiac output. Sustained high rates initiate a progressive clinical cascade:


Clinical Case: Fetal echocardiogram demonstrating sustained SVT (>220 bpm) with associated cardiomegaly and pericardial effusion (hydrops fetalis). (From the author’s clinical practice.)

The Placental Transfer Breakdown in Hydrops

As central venous pressures rise, the fetus develops marked systemic venous congestion, ascites, pericardial/pleural effusions, and progressive placental villous edema. This creates the primary pharmacokinetic challenge of digoxin:

Comparison of transplacental transfer for Digoxin vs Flecainide in normal gestation versus severe placental villous edema in hydrops fetalis
Figure: Mechanism of transplacental transfer failure in hydrops fetalis. Hydrophilic, bulky molecules like digoxin are trapped in edematous placental villi, while lipophilic flecainide reliably diffuses across into the fetal circulation.

The Molecular Basis of Transfer Impairment

Digoxin is a relatively hydrophilic cardiac glycoside that crosses the placenta via passive diffusion across the syncytiotrophoblast. In an uncomplicated placenta, maternal-fetal equilibrium yields a fetal-to-maternal concentration ratio of approximately 0.70 to 0.85 (Weiner et al. 1989; Azancot-Benisty et al. 1992). However, when placental edema develops, transplacental passage of digoxin decreases to approximately 0.20–0.30 (Ito et al. 1994). In contrast, flecainide is lipophilic with modest protein binding, maintaining a steady fetal-to-maternal concentration ratio of approximately 0.80 to 1.0 even in the presence of severe hydrops (Krapp et al. 2002; Jaeggi et al. 2011).

Transplacental transfer of Digoxin vs Flecainide in normal gestation versus hydrops fetalis
Figure 2: Transplacental Passage: Digoxin fetal: maternal ratio decreases in edematous villi, whereas Flecainide reliably crosses the placental barrier.

2. The Evidence Base & Batra et al. 2024 AHA/PACES Guidelines

The transition toward flecainide and sotalol reflects extensive clinical experience synthesized in international electrophysiology and cardiology statements:

The 2024 AHA Scientific Statement (Batra et al., Circulation 2024)

Endorsed by PACES

Published in early 2024, the American Heart Association Scientific Statement titled “Pharmacological Management of Cardiac Arrhythmias in the Fetal and Neonatal Periods” (Batra AS, Silka MJ, Jaeggi E, et al.) provides a modern synthesis of fetal tachyarrhythmia management:

  • Guideline Perspective: The statement notes that flecainide and sotalol, rather than digoxin monotherapy, have increasingly become preferred first-line medications for fetal SVT and atrial flutter across specialized centers.
  • Comparative Evidence: Multicenter observational cohorts indicate faster cardioversion and higher overall efficacy for flecainide over digoxin, especially in fetuses presenting with ventricular dysfunction or hydrops.
  • Multi-Disciplinary Care: Recommends formal co-management by pediatric/fetal cardiologists, maternal-fetal medicine subspecialists, and electrophysiologists.
  • Maternal Safety Screening: Recommends baseline maternal 12-lead ECG (and maternal echocardiogram when feasible) before initiating Class IC agents to evaluate structural anatomy and exclude underlying conduction disease.

Foundational Clinical Studies Supporting Current Practice

  • Jaeggi et al. (Circulation 2011; 159 fetuses): In a landmark multicentre cohort, flecainide (HR = 2.1, p = 0.02) and digoxin (HR = 2.9, p = 0.01) showed superior hazard ratios over sotalol for converting SVT to sinus rhythm over time. In Atrial Flutter, Sotalol demonstrated a significantly higher hazard ratio for termination (HR = 5.4 vs. digoxin, p = 0.05; HR = 7.4 vs. flecainide, p = 0.03).
  • Alsaied et al. (JAHA 2017; 537 fetuses, 10 studies): Systematic review and meta-analysis demonstrating that first-line flecainide was associated with higher conversion rates than digoxin, an effect particularly pronounced in hydropic fetuses where digoxin showed significantly lower conversion success (OR = 0.412; 95% CI: 0.268–0.632).
  • Hill et al. (Prenat Diagn 2017; 21 studies): Systematic review confirming that first-line monotherapy with flecainide or sotalol achieved high rates of conversion in fetal tachyarrhythmias, maintaining efficacy even when transplacental transfer of hydrophilic agents was impeded.

Fetal antiarrhythmic selection matrix comparing flecainide, digoxin, and sotalol
Figure 3: Antiarrhythmic Selection Matrix based on Batra et al. 2024 AHA/PACES recommendations.

🪜 Stepwise Escalation Matrix: When First-Line Therapy Fails

Based on Batra et al. 2024 AHA/PACES Scientific Statement & multicenter protocols

1
Step 1 — First-Line Monotherapy

Start Here

For SVT:
Flecainide 100 mg PO TID
For Atrial Flutter:
Sotalol 80–160 mg PO BID
⏱️ Assess response: Daily fetal echo + maternal 12-lead ECG. Monitor closely over 3–5 days for cardioversion before considering dose escalation or secondary agents.

⬇ NO CARDIOVERSION AFTER 3–5 DAYS

2
Step 2 — Combination Therapy

Escalate

Add Digoxin to existing agent (IV loading → oral maintenance)
Rationale: Synergistic AV nodal blockade. Digoxin slows the anterograde limb; flecainide blocks the retrograde accessory pathway.
⏱️ Assess response: Continue daily fetal echo + maternal ECG + digoxin levels. Allow 3–5 additional days.

⬇ STILL REFRACTORY / HYDROPS WORSENING

3
Step 3 — Switch Antiarrhythmic Class

Expert Decision

Replace flecainide with sotalol (or vice versa) ± digoxin combination
Rationale: Different mechanism (Class III vs IC) may overcome resistance.
⚠️ Never combine flecainide + sotalol (extreme proarrhythmic risk)
⏱️ Assess response: Washout period required. Restart maternal ECG monitoring from new baseline. Allow 5–7 days.

⬇ REFRACTORY + DETERIORATING FETUS

4
Step 4 — Rescue Therapy

Critical / Last Resort

Option A: Amiodarone
Maternal IV amiodarone loading
⚠️ Fetal hypothyroidism risk (10–20%)
Monitor neonatal TSH
Option B: Direct Fetal Therapy
Ultrasound-guided direct fetal injection
(Digoxin or amiodarone IM / umbilical vein)
Specialised fetal centers only for critical demise risk

⬇ REFRACTORY TO ALL PHARMACOTHERAPY

5
Step 5 — Delivery Decision

Multidisciplinary Decision

If ≥34 weeks: Consider delivery for ex-utero cardioversion (DC cardioversion, IV adenosine, postnatal amiodarone)
If <34 weeks: Maximise transplacental therapy + antenatal steroids. Weigh risk of prematurity vs. progressive hydrops.
If previable / extreme prematurity: Compassionate care counselling, continued maternal therapy, and serial reassessment.

⚠️ Key Safety Principles Across All Steps:

  • Never combine flecainide + sotalol (additive QRS + QT prolongation → dangerous proarrhythmia)
  • Daily maternal 12-lead ECG with every dose adjustment or drug switch
  • QRS widening ≥20% or QTc >480 ms → withhold dose and request urgent electrophysiology consultation
  • Inpatient admission is required for initiation and escalation across all steps

3. The FAST Trial Paradigm: What It Investigated & What We Await

To evaluate comparative efficacy through randomized methodology, the multicenter FAST (Fetal Atrial Flutter and Supraventricular Tachycardia) Therapy Trial (NCT02624765) and its registry arm (NCT03376438) were initiated by Dr. Edgar Jaeggi and international investigators.

Structure of the FAST Trial (3 Prospective Sub-Studies)

Sub-Study A: Atrial Flutter (Non-Hydropic)
Randomized head-to-head: Digoxin monotherapy vs. Sotalol monotherapy.
Sub-Study B: SVT (Non-Hydropic)
Randomized head-to-head: Digoxin monotherapy vs. Flecainide monotherapy.
Sub-Study C: SVT (Hydropic)
Randomized dual therapy: Digoxin + Sotalol vs. Digoxin + Flecainide.

Trial Architecture & Registered Endpoints

According to study registries, the FAST trial (NCT02624765, 105 enrolled) and its accompanying registry (NCT03376438, 330 enrolled) completed data collection with follow-up through neonatal hospital discharge (30 days of life). The primary registered trial endpoint focuses on the proportion of live-born children with a delivery at term and a normal cardiac rhythm. Key secondary outcomes include:

  • Time-to-cardioversion curves for randomized regimens.
  • Treatment failure and cross-over frequency between drug arms.
  • Maternal safety, including incidence of proarrhythmia or intolerable side effects.
  • Arrhythmia-related death, gestational age at delivery, and neonatal outcomes at 30 days of life.

Note: Registered trial exclusions included pregnancies ≥36 weeks, severe fetal abnormalities (such as trisomy 13 or 18, or conditions anticipated to require surgery or cause demise within 1 month of life), maternal Wolff-Parkinson-White syndrome, or asthma.

4. Practical Protocol: Dosing & Bedside ECG Surveillance

Administering transplacental antiarrhythmic therapy requires strict inpatient safety controls. As emphasized in Batra et al. 2024, maternal blood levels do not always correlate directly with fetal efficacy; thus, daily maternal 12-lead ECG monitoring serves as the indispensable bedside safety surrogate.

Maternal QRS duration bedside safety surveillance protocol for flecainide
Figure 4: Bedside Maternal QRS Surveillance Protocol for Flecainide Titration.
⚠️ Mandatory Clinical Standard: Inpatient Initiation Only

Transplacental flecainide must strictly be initiated under the direct supervision of a pediatric/fetal cardiologist and maternal-fetal medicine specialist in an inpatient or monitored tertiary facility. Outpatient management is reserved strictly for stable maintenance after documented cardioversion and normal maternal ECG.

  1. Maternal Baseline Workup: Baseline 12-lead ECG (confirm normal PR interval, normal QRS duration <100 ms, normal QTc). Baseline maternal echocardiogram (to evaluate ventricular anatomy/function). Baseline electrolytes (K+, Mg++, Ca++) and renal function.
  2. Starting Dosage: Maternal oral Flecainide 100 mg every 8 hours (300 mg/day). In smaller gravidas (<50 kg), initial dosing may be initiated at 50–100 mg BID.
  3. Primary Bedside Monitoring — Daily 12-Lead ECG:
    Because serum flecainide assay availability is variable across clinical laboratories, serial maternal 12-lead ECG QRS duration measurement is the indispensable real-time clinical surrogate for drug toxicity:

    • Baseline Reference: Record exact baseline QRS duration (typically 80–90 ms).
    • Safety Limit: Hold or reduce dose if QRS duration widens by ≥20% over baseline.
    • Absolute Cutoff: Withhold dose and re-evaluate immediately if the absolute QRS duration exceeds 120 ms (or PR interval prolongs by >50%).
  4. Serum Trough Levels (Dependent on Lab Availability):
    Where timely therapeutic drug monitoring is accessible, draw maternal trough levels at steady state (day 3–4, immediately before a morning dose).

    • Target Therapeutic Range: 0.2 to 1.0 mcg/mL.
    • Toxicity Alert: Levels >1.0 mcg/mL carry significantly increased proarrhythmic risk. However, when laboratory assays are unavailable or delayed by several days, rigorous daily maternal QRS monitoring remains the cornerstone of safe titration.
  5. Fetal Response Surveillance: Daily fetal echocardiography and continuous fetal heart rate monitoring to verify cardioversion, evaluate ventricular myocardial function, and track resolution of effusion/hydrops.

🎯 Summary for Clinical Practice

The reflexive use of digoxin monotherapy for all fetal SVT presentations has evolved. Supported by the 2024 AHA/PACES Scientific Statement (Batra et al.) and multicenter registries, transplacental flecainide has become an established primary therapy for fetal SVT due to its preserved transplacental passage in the setting of hydrops. When published, the primary randomized outcomes of the international FAST trial will provide prospective randomized evidence regarding these comparative strategies.

References & Evidence Base

  1. Batra AS, Silka MJ, Borquez A, Cuneo B, Dechert B, Jaeggi E, Kannankeril PJ, Tabulov C, Tisdale JE, Wolfe D; on behalf of the American Heart Association and PACES. Pharmacological Management of Cardiac Arrhythmias in the Fetal and Neonatal Periods: A Scientific Statement From the American Heart Association. Circulation. 2024;149(10):e937–e952. Epub 2024 Feb 5. doi:10.1161/CIR.0000000000001206.
  2. Jaeggi ET, Carvalho JS, De Groot NM, et al. Comparison of transplacental treatment of fetal supraventricular tachyarrhythmias with digoxin, flecainide, and sotalol: results of a nonrandomized multicenter study. Circulation. 2011;124(16):1747-1754. doi:10.1161/CIRCULATIONAHA.111.026120.
  3. Alsaied T, Baskar S, Fares M, et al. First-Line Antiarrhythmic Transplacental Treatment for Fetal Tachyarrhythmia: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2017;6(12):e007164. doi:10.1161/JAHA.117.007164.
  4. Hill GD, Kovach JR, Saudek DE, Singh AK, Wehrheim K, Frommelt MA. Transplacental treatment of fetal tachycardia: A systematic review and meta-analysis. Prenat Diagn. 2017;37(11):1076–1083. doi:10.1002/pd.5144.
  5. Jaeggi E, et al. Prospective Randomized Clinical Trial of Fetal Atrial Flutter and Supraventricular Tachycardia Therapy (FAST). ClinicalTrials.gov. Identifier: NCT02624765.
  6. Jaeggi E, et al. FAST Registry: Fetal Atrial Flutter and Supraventricular Tachycardia Therapy Trial. ClinicalTrials.gov. Identifier: NCT03376438.
  7. Donofrio MT, Moon-Grady AJ, Hornberger LK, et al. Diagnosis and Treatment of Fetal Cardiac Disease: A Scientific Statement From the American Heart Association. Circulation. 2014;129(21):2183-2242. doi:10.1161/01.cir.0000437597.44550.5d.
  8. Weiner CP, Landas S, Persoon TJ. Digoxin transport across the human placenta: in vivo and in vitro observations. Am J Obstet Gynecol. 1989;161(2):360-364. doi:10.1016/0002-9378(89)90520-2.
  9. Ito S, Magee L, Smallhorn J. Drug therapy for fetal arrhythmias. Clin Perinatol. 1994;21(3):543-572.
  10. Krapp M, Baschat AA, Gembruch U, et al. Flecainide in the intrauterine treatment of fetal supraventricular tachycardia. Ultrasound Obstet Gynecol. 2002;19(2):158-164. doi:10.1046/j.0960-7692.2001.00624.x.

Standard of Evidence: Synthesised from the 2024 AHA/PACES Scientific Statement (Batra et al.), international multicenter cohorts (Jaeggi 2011), meta-analyses (Alsaied 2017, Hill 2017), the FAST trial architecture (NCT02624765), and current fetal cardiology guidelines.
Disclaimer: This review is intended for healthcare professionals and does not replace individualized clinical judgment or institutional protocols.